GlassScriptPhysician profile
Paul L Dalbec
NPI 1912922527
$3,861.26
in general payments reported to CMS, 2019-2025
28 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.24 · 2020: $23.69 · 2021: $62.00 · 2022: $546 · 2023: $1,220 · 2024: $889 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.10 | 2022-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.03 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $461.94 | 2022-2025 | |
| Glaxosmithkline, LLC. | $356.44 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $335.58 | 2023-2025 | Farxiga, Breztri |
| Vanda Pharmaceuticals INC. | $163.69 | 2025 | Fanapt |
| Lilly USA, LLC | $153.69 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Genentech USA, INC. | $103.93 | 2019-2021 | |
| Axsome Therapeutics, INC. | $98.41 | 2023-2024 | Sunosi, Auvelity |
| Neurocrine Biosciences, INC. | $94.54 | 2024 | Ingrezza |
| Novo Nordisk INC | $87.01 | 2023-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $77.10 | 2022 | |
| Amgen INC. | $75.98 | 2023-2025 | Otezla, Repatha, Repatha |
| Corcept Therapeutics | $58.27 | 2024 | Korlym |
| Lundbeck LLC | $53.67 | 2022-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $47.59 | 2023 | Ztlido |
| Alkermes, INC. | $45.28 | 2023-2025 | Vivitrol, Vivitrol |
| Ani Pharmaceuticals, INC. | $43.74 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $35.61 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $34.94 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.19 | 2022 | |
| Ardelyx, INC. | $23.33 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $22.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.28 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $20.49 | 2024 | Dupixent |
| Otsuka America Pharmaceutical, INC. | $16.41 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $14.73 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dalbec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.